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Abstract 
New fluorinated and methoxylated di(hetero)arylethers and di(hetero)arylamines were 
prepared functionalizing the 7-position of the thieno[3,2-b]pyridine, using copper  (C-
O) or palladium (C-N) catalyzed couplings, respectively, of the 7-bromothieno[3,2-
b]pyridine, also prepared, with ortho, meta and para fluoro or methoxy phenols and 
anilines. The compounds obtained were evaluated for their growth inhibitory activity on 
the human tumor cell lines MCF-7 (breast adenocarcinoma), NCI-H460 (non-small cell 
lung cancer), HCT15 (colon carcinoma), HepG2 (hepatocellular carcinoma) and HeLa 
(cervical carcinoma). The most active compounds, a di(hetero)arylether with a methoxy 
group in the meta position relative to the ether function  and two di(hetero)arylamines 
with a methoxy group either in the ortho or in the meta position relative to the NH, were 
further tested at their GI50 concentrations on NCI-H460 cells causing pronounced 
alterations in the cell cycle profile and a strong and significant increase in the 
programmed death of these cells. The fluorinated and the other methoxylated 
compounds did not show important activity, presenting high GI50 values in all the cell 
lines tested. Furthermore, the hepatotoxicity of the compounds was assessed using 
porcine liver primary cells (PLP2), established by some of us. Results showed that one 
of the most active compounds was not toxic to the non-tumor cells at their GI50 
concentrations showing to be the most promising as antitumoral.  
 
 
 
Keywords: Di(hetero)arylethers; Di(hetero)arylamines, Thieno[3,2-b]pyridines; Metal-
catalyzed couplings; Tumor and non tumor cells growth inhibition; Cell cycle analysis 
and cell death (NCI-H460) 
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1. Introduction 
 
The thienopyridine skeleton has been reported as having interesting biological activities 
namely antitumoral [1-7] and antiangiogenic [8-12]. Sugano et al. reported that the (3-
amino-6-thien-2-yl-thieno[2,3-b]pyridin-2-yl)arylmethanones I showed selectivity 
against a tumorigenic cell line, in very low EC50 values [1]. The methyl 3-amino-6-
benzo[d]thiazol-2-ylamino)thieno[3,2-b]pyridine-2-carboxylat II was previously 
prepared by us and showed to be the most active compound in a series of methyl 3-
amino-6-[(hetero)arylamino]thieno[3,2-b]thienopyridine-2-carboxylates [2]. In the 3-
amino-6-[(hetero)aryl]thieno[3,2-b]pyridine-2-carboxylate series, compounds III and 
IV were shown to be the most promising compounds against MCF-7 (breast 
adenocarcinoma), A375-C5 (melanoma) and NCI-H460 (non-small cell lung cancer) 
cell lines. Indeed, compound III showed selectivity against MCF-7 and NCI-H460, 
presenting very low GI50 values (1 µM) and compound IV presented GI50 values in the 
3-4 µM range for the three cell lines. The effects of compounds III and IV on the cell 
cycle profile of NCI-H460 cells pointed to different mechanisms of action for each 
compound [3]. Several methyl 3-amino-6-[(hetero)arylethynyl]thieno[3,2-b]pyridine-2-
carboxylates have also been prepared by us and studied against the same human tumor 
cell lines, compounds Va-c being the most potent ones. Effects of these three 
compounds on the cell cycle profile of the NCI-H460 cells were observed and 
compound Vb was found to significantly induce apoptosis at its GI50 in this cell line [4]. 
Recently we have prepared methoxylated di(hetero)arylethers functionalizing the 6-
position of the same thieno[3,2-b]pyridine moiety. The compounds with a methoxy 
group in ortho (VIa) or meta (VIb) relative to the ether function showed very low GI50 
values (1-2.5 µM). These compounds are fluorescent and have been encapsulated into 
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nanoliposomes for drug delivery purposes [5]. In another study, compound Vd showed 
a very low GI50 value (1.2 µM) in the HepG2 hepatocellular carcinoma cells with no 
hepatotoxicity to porcine liver primary cells. Effects of this compound on the cell cycle 
of HepG2 were verified [6]. By functionalizing the amino group of the 3-
aminothieno[3,2-b]pyridine-2-carboxylate, several amino diarylamines were obtained. 
Among them, compound VII was the most active presenting very low GI50 values (1 
µM) for all the cell lines referred above including HepG2, without hepatotoxicity to 
porcine liver primary cells. Effects on the cell cycle profile of the NCI-H460 cells 
treated with compound VII were observed [7].  
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N-(1H-indol-5-yl)-2-arylthieno[3,2-b]pyridin-7-amines [8], aminothieno[3,2-c]pyridine 
1,3-diarylureas [9],  thieno[3,2-b]pyridine arylethers phenylacetylthioureas [10],  
thieno[3,2-b]pyridine arylethers N3-arylmalonamides [11], and N-(3-fluoro-4-(2-
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arylthieno[3,2-b]pyridin-7-yloxy)phenyl)-2-oxo-3-phenylimidazolidine-1-carboxamides 
[12] have been previously described as inhibitors of the vascular endothelial growth 
factor receptor (VEGFR-2), a mediator of the biological function of the vascular 
endothelial growth factor (VEGF), related to angiogenesis and metastasis. 
In the present study, new fluorinated and methoxylated di(hetero)arylethers and 
di(hetero)arylamines were prepared by functionalizing the 7-position of the thieno[3,2-
b]pyridine, using copper  (C-O) or palladium (C-N) catalyzed couplings, respectively. 
The compounds were evaluated for their growth inhibitory activity towards human 
tumor cell lines, and the most active ones were further studied regarding their effects on 
NCI-H460 cell cycle profile and programmed cell death. The hepatotoxicity of the 
compounds was assessed using non-tumor porcine liver primary cells. 
 
2. Results and discussion 
 
2.1. Synthesis 
 
The reaction of the 7-bromothieno[3,2-b]pyridine (1), also prepared by us from the 
commercial thieno[3,2-b]pyridin-7-ol and POBr3, with  methoxy or fluorophenols and 
anilines gave rise in moderate to good yields to the new di(hetero)arylethers 2a-f,  by a 
copper-catalyzed (C-O) Ullmann coupling with N,N-dimethyl glycine as the ligand [13], 
previously used by us in the synthesis of other di(hetero)arylethers [5], and in good to 
high yields to the new di(hetero)arylamines 3a-f by a palladium-catalyzed (C-N) 
Buchwald-Hartwig coupling [14] with BINAP as the ligand, usually performed in our 
group [2] (Scheme 1). 
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Scheme 1. Synthesis of di(hetero)arylethers 2a-f and di(hetero)arylamines 3a-f by 
copper (C-O) and palladium (C-N) catalyzed couplings, respectively. 
 
2.2. Growth inhibitory activity on human tumor cell lines and on porcine liver 
primary cells 
 
The tumour cell growth inhibitory activity of the di(hetero)arylethers 2a-f and 
di(hetero)arylamines 3a-f was evaluated in five human tumor cell lines: MCF-7 (breast 
adenocarcinoma), NCI-H460 (non-small cell lung carcinoma), HCT15 (colon 
adenocarcinoma), HepG2 (hepatocellular carcinoma)  and HeLa (cervical carcinoma) 
using the sulforhodamine B assay as previously described [2-7]. This allowed the 
determination of the GI50 values (µM), corresponding to the concentration of the 
compounds which inhibited 50% of cell growth (Table 1). Furthermore, the toxicity of 
the compounds towards non-tumor cells was studied using porcine liver primary cells 
(PLP2) .  
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Table 1. Growth inhibitory activity of the synthesized di(hetero)arylethers 2a-f and 
di(hetero)arylamines 3a-f on various human tumor cell lines and in non-tumor porcine 
liver primary cells (PLP2). 
GI50 (uM)a 
 HepG2 HeLa MCF-7 NCI-H460 HCT15 PLP2 
2a 16.43 ± 0.74 50.26 ± 2.47 74.29 ± 1.98 77.96 ± 3.98 97.22 ± 4.48 87.24 ± 4.29 
2b 42.65 ± 3.12 34.51 ± 4.09 101.83 ± 8.40 102.65 ± 8.54 103.47 ± 1.61 >125 
2c 45.10 ± 1.97 33.83 ± 2.30 98.48 ± 7.52 100.60 ± 5.90 88.08 ± 4.91 >125 
2d 62.68 ± 4.22 28.94 ± 7.03 90.89 ± 5.01 94.17 ± 4.47 91.15 ± 5.21 >125 
2e 2.70 ± 0.41 3.14 ± 0.12 1.56 ± 0.23 1.04 ± 0.04 0.39 ± 0.03 26.65 ± 1.98 
2f 53.24 ± 4.65 49.4 ± 1.52 93.31 ± 4.86 86.77 ± 5.39 86.05 ± 4.24 94.45 ± 6.09 
3a 25.8 ± 2.81 26.37 ± 2.93 94.37 ± 4.26 79.51 ± 1.94 86.65 ± 6.04 114.91 ± 6.92 
3b 32.02 ± 2.33 69.24 ± 5.18 63.71 ± 3.78 77.47 ± 2.50 70.65 ± 5.67 119.46 ± 5.97 
3c 26.26 ± 2.56 77.49 ± 3.83 80.74 ± 6.01 78.46 ± 6.56 91.16 ± 5.34 100.41 ± 4.41 
3d 18.00 ± 1.29 1.40 ± 0.06 5.88 ± 0.86 5.40 ± 0.89 5.91 ± 0.21 6.56 ± 0.2 
3e 5.02 ± 0.06 0.09 ± 0.00 0.25 ± 0.03 0.28 ± 0.03 0.31 ± 0.04 1.94 ± 0.16 
3f 22.08 ± 2.11 20.42 ± 2.24 20.20 ± 1.31 19.44 ± 1.44 25.92 ± 1.83 22.73 ± 2.02 
Ellipticine 5.38 ± 1.11 3.28 ± 0.67 4.32 ± 1.03 5.77 ± 0.95 1.91 ± 0.06 2.06 ± 0.03 
aGI50 values correspond to the compound concentration which inhibited 50% of cell growth. Results are 
from three independent experiments (performed in triplicate), and are expressed as mean ± standard 
deviation (SD). 
 
From the results obtained (Table 1) it is possible to establish some structure-activity 
relationships. Among the di(hetero)arylethers 2a-f, compound 2e, m-methoxylated, 
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showed the lowest GI50 values in the different tumor cell lines (0.39-3.14 µM), in 
particular in the HCT15 cell line (0.39 µM). The other methoxylated compounds, 2d 
and 2f, were not very efficient inhibitors of cell growth. The fluorinated compounds 2a-
c presented no significant growth inhibitory activity against the five cell lines studied, 
presenting high GI50 values. 
The di(hetero)arylethers 2a and 2f presented GI50 values in the PLP2 cells similar to the 
GI50 values obtained in most of the human tumor cell lines (except in the HepG2 and in 
the HeLa cells, in which the GI50 values were lower than in the primary cells). 
Nonetheless, the di(hetero)arylethers 2b-2e presented lower GI50 values in the tumor 
cell lines than in the PLP2. 
Regarding the di(hetero)arylamines 3a-f, the most active compounds are 3d and 3e. 
These compounds, with o-methoxy or m-methoxy groups relative to the NH, presented 
the lowest GI50 values in the tumor cell lines studied but also presented low GI50 values 
in the non-tumor PLP2 cells. Nevertheless for compound 3d, the GI50 determined for the 
HeLa cell line (1.40 µM) was very much lower than the GI50 (6.56 µM) for the PLP2 
cells. Also, for compound 3e, which was the most active compound, the GI50 
determined for most of the tumor cell lines (0.09-0.31 µM), with the exception of the 
HepG2 cells (5.02 µM), were slightly lower than the GI50 in PLP2 cells (1.94 µM). The 
fluorinated compounds 3a-c presented much higher GI50 values than the metoxylated 
ones, for the inhibitory growth activity in the tumor cell lines studied and presented 
higher GI50 values in the PLP2 cells than in most of the tumor cell lines studied. On the 
other hand, the p-methoxylated compound 3f presented similar GI50 values in the tumor 
cells and primary cells. 
The most active compounds in the tumor cell lines, 2e, 3d and 3e, were chosen to be 
further studied regarding their effect on cell cycle profile and programmed cell death on 
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one of the most sensitive cell lines, NCI-H460. This cell line was also chosen since it 
represents non-small cell lung cancer, one of the cancers which currently cause most 
deaths worldwide. 
 
2.3. Effects on cell cycle profile and programmed cell death of NCI-H460 cells  
 
Treatment of NCI-H460 cells with the GI50 concentration of compounds 2e, 3d and 3e 
showed that all the compounds caused pronounced alterations in the cell cycle profile of 
these cells (Figure 1). In addition, a shoulder in the left of the G1 peak was evident 
following treatment with all the compounds, which was indicative of a sub-G1 peak and 
suggestive of cell death.  
This was further confirmed with the TUNEL assay. Indeed, a strong and significant 
increase in programmed cell death was observed following 24h and 48h of treatment 
with the compounds (Figure 2). When cells were treated with the compounds for 24h, 
compounds 3d and 3e caused a stronger increase than compound 2e in the levels of cell 
death. However, when cells were treated for 48h all compounds caused similar effects 
in the levels of cell death, which was higher than 30%. 
10 
 
 
 
Figure 1. Analysis of cell cycle profile by flow cytometry of NCI-H460 cells treated 
with the compounds. Cells were treated for 24 h with medium (A), DMSO (B), or the 
GI50 concentrations of compounds 2e (C), 3d (D) or 3e (E). The left panel corresponds 
to dot plots of forward versus side scatter (FSC versus SSC) and shows the gated 
population. In the right panel, the histograms indicate the cell cycle profile of the gated 
population following the exclusion of cellular aggregates and debris. All images are 
representative of three independent experiments.  
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B. 
 
Figure 2. Analysis of programmed cell death of NCI-H460 cells treated with the 
compounds. Cells were treated for 24 h (A) or 48h (B) with medium, DMSO, or the 
12 
 
GI50 concentrations of compounds 2e, 3d and 3e. Levels of programmed cell death were 
determined with the TUNEL assay. Results are the mean ± SEM of three independent 
experiments. Statistical significance was tested by two tailed paired Student’s t-Test 
using DMSO as a negative control. * Indicates p<0.05. 
 
 
3. Conclusions 
The fluorinated and methoxylated di(hetero)aryl)ethers and di(hetero)arylamines were 
prepared by copper (C-O) or palladium (C-N) catalyzed couplings of 7-
bromothieno[3,2-b]pyridine with ortho, meta and para fluoro or methoxy phenols or 
anilines in moderate to high yields, after chromatographic purification and were fully 
characterized. The compounds obtained were evaluated for their growth inhibitory 
activity on several human tumor cell lines. The most active compounds, were shown to 
be a di(hetero)arylether with a methoxy group in the meta position relative to the ether 
function and two di(hetero)arylamines with a methoxy group either in the ortho or in 
the meta position relative to the NH. These were further tested at their GI50 
concentrations on NCI-H460 cells causing pronounced alterations in the cell cycle 
profile and a strong and significant increase in the programmed death of these cells. The 
fluorinated and the other methoxylated compounds presented high GI50 values in all the 
cell lines tested. Furthermore, the toxicity of the compounds was assessed using porcine 
liver primary cells (PLP2). The results showed that one of the most active compounds, 
the di(hetero)arylether 2e, was non toxic to non-tumor cells at their GI50 concentrations, 
compound 2e being the most promising antitumoral. The toxicity of the two 
di(hetero)arylamines 3d and 3e needs to be further studied. 
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4. Materials and Methods 
 
4.1 Chemistry 
 
Melting points (oC) were determined in a Stuart SMP3 and are uncorrected. 1H and 
13CNMR spectra were recorded on a Varian Unity Plus at 300 and 75.4 MHz, 
respectively or on a BrukerAvance III at 400 and 100.6 MHz, respectively. Two 
dimensional 1H-13C correlations were performed to attribute some signals. Mass spectra 
(MS) EI -TOF or ESI-TOF and HRMS on the M+ or on the [M+H]+ were performed by 
the mass spectrometry service of the University of Vigo, C.A.C.T.I., Spain. The 
reactions were monitored by thin layer chromatography (TLC) using Macherey-Nagel 
pre-coated aluminum silica gel 60 sheets (0.20 mm) with UV254 indicator. Column 
cromatography was performed on Panreac, Silica Gel 60, 230-400 mesh and the dry 
flash on silica was performed on Panreac, Silica Gel 60, 70-230 mesh.Ether refers to 
diethylether. Petroleum ether refers to the boiling range 40-60 ºC. 
 
4.1.1. 7-Bromothieno[3,2-b]pyridine (1): From thieno[3,2-b]pyridin-7-ol (300 mg, 2.00 
mmol) and POBr3 (2.80 g, 10.0mmol) and the mixture was heated at 65 ºC for 6h. After 
cooling, NaOH (aq) (5mL), water (5mL) and chloroform (5mL) were added. The phases 
were separated and the aqueous phase was extracted with more chloroform (2×5mL). 
The organic phase was dried (MgSO4) and filtered. Removal of the solvent gave 
compound 1as a yellow solid (363mg, 85%), m.p. 67-68ºC. 1H NMR (400MHz,CDCl3): 
δ 7.46 (d, J = 5.2 Hz, 1H, 6-H), 7.67 (d, J = 5.6 Hz, 1H, HetArH), 7.83 (d, J = 5.6 Hz, 
1H, HetArH), 8.51 (d, J = 5.2 Hz, 1H, 5-H) ppm. 13CNMR (100.6MHz, CDCl3): δ 121.7 
(6-CH), 125.9 (CH), 126.9 (C), 131.4 (CH), 135.7 (C), 147.5 (5-CH), 156.4 (C) ppm. 
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HRMS (EI-TOF):Calcd for C7H479BrNS [M]+ 212.9248. Found 212.9248.Calcd for 
C7H481BrNS [M]+ 214.9227. Found 214.9227. 
 
4.1.2 General procedure for the synthesis of di(hetero)arylethers 2a-f: A dry Schlenk 
tube was charged under Ar with dry dioxane (3 mL), the fluoro or methoxyphenol (1.1 
equiv.), N,N-dimethylglycine (30 mol%), CuI (20 mol%),  Cs2CO3 (2 equiv.) and 
compound1. The mixture was heated with stirring under Ar at 100 ºC for 18h. After 
cooling water (5mL) and ethyl acetate (5mL) were added. The phases were separated 
and the aqueous phase was extracted with more ethyl acetate (2×5mL). The organic 
phase was dried (MgSO4) and filtered. Removal of the solvent gave anoil which was 
submitted to column chromatography. 
 
4.1.2.1. 7-(2-flurophenoxy)thieno[3,2-b]pyridine (2a): Compound 1 (100 mg, 
0.470mmol), 2-fluorophenol, and after purification by column chromatography using a 
solvent gradient from 50% to 65% ether/petroleum ether, compound 2awas obtained as 
a white oil (81.0 mg, 70%). 1H NMR (400 MHz, CDCl3): δ 6.54 (d, J = 4.8 Hz, 1H, 6-
H), 7.22-7.33 (m, 4H, Ar-H), 7.64 (d, J = 5.6 Hz, 1H, HetAr-H), 7.80 (d, J = 5.6 Hz, 
1H, HetAr-H), 8.54 (br s, 1H, 5-H) ppm. 13CNMR (100.6 MHz, CDCl3): δ 103.2 (6-
CH), 117.5 (d, J = 18.1 Hz, 3’-CH), 122.4 (C), 123.6 (CH), 124.9 (CH), 125.2 (d, J = 
4.0 Hz, 4’-CH), 127.4 (d, J = 7.0 Hz, 6’-CH), 131.3 (CH), 140.6 (d, J = 12.1 Hz, 1’-C), 
148.6 (5-CH), 153.3 (C), 157.0 (d, J = 251.5 Hz, CF), 160.1 (C) ppm. HRMS (EI-TOF): 
Calcd for C13H8FNOS [M+] 245.0311. Found 245.0305. 
 
4.1.2.2. 7-(3-flurophenoxy)thieno[3,2-b]pyridine (2b):From compound 1 (100 mg, 
0.470 mmol), 3-fluorophenol, and after purification by column chromatography using a 
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solvent gradient from 30% to 50% ether/petroleum ether, compound 2bwas obtained as 
a white oil (72.0 mg, 63%). 1H NMR (400 MHz, CDCl3): δ 6.64 (d, J = 5.2 Hz, 1H, 6-
H), 6.92-7.04 (m, 3H, Ar-H), 7.39-7.44 (m, 1H, Ar-H), 7.60 (d, J = 5.6 Hz, 1H, HetAr-
H), 7.77 (d, J = 5.6 Hz, 1H, HetAr-H), 8.56 (br s, 1H, 5-H) ppm. 13CNMR (100.6 
MHz,CDCl3): δ 104.7 (6-CH), 108.7 (d, J = 24.1 Hz, CH), 112.8 (d, J = 21.1 Hz, CH), 
116.4 (d, J = 3.0 Hz, 6’-CH), 123.0 (C), 125.2 (CH), 130.9 (CH), 131.0 (d, J = 10.0 Hz, 
5’-CH), 148.99 (5-CH), 154.9 (d, J = 11.1 Hz, 1’-C), 158.9 (C), 159.6 (C), 163.4 (d, J = 
248.4 Hz, CF) ppm. HRMS (EI-TOF): Calcd for C13H8FNOS [M+] 245.0311. Found 
245.0313. 
 
4.1.2.3. 7-(4-flurophenoxy)thieno[3,2-b]pyridine (2c): From compound 1 (100 mg, 
0.470 mmol) and 4-fluorophenol, and after purification by column chromatography 
using a solvent gradient from 40% to 60% ether/petroleum ether, compound 2cwas 
obtained as a white oil (75.0 mg, 65%). 1H NMR (400 MHz, CDCl3): δ 6.54 (d, J = 5.2 
Hz, 1H, 6-H), 7.13-7.20 (m, 4H, Ar-H), 7.60 (d, J = 5.6 Hz, 1H, HetAr-H), 7.76 (d, J = 
5.6 Hz, 1H, HetAr-H), 8.52 (br s, 1H, 5-H) ppm. 13CNMR (100.6 MHz, CDCl3): δ 
103.9 (6-CH), 116.9 (d, J = 23.1 Hz, 3’and 5’-CH), 122.6 (d, J = 9.0Hz, 2’and 6’-CH), 
124.9(C), 125.2 (CH), 130.9 (CH), 148.9 (5-CH), 149.5 (d, J = 3.0 Hz, 1’-C), 158.8 (C), 
158.88 (d, J = 245.0 Hz, CF), 160.5 (C) ppm. HRMS (EI-TOF): Calcd for C13H8FNOS 
[M+] 245.0311. Found 245.0314. 
 
4.1.2.4. 7-(2-methoxyphenoxy)thieno[3,2-b]pyridine (2d):From compound 1 (140 mg, 
0.488 mmol), 2-methoxyphenol, and after purification by column chromatography using 
a solvent gradient from 25% ether/petroleum ether to 30% ether/petroleum ether, 
compound 2d was obtained as a yellow oil (55.0 mg, 50%). 1H NMR (300 MHz, 
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CDCl3): δ 3.76 (s, 3H, OMe), 6.43 (d, J = 5.7 Hz, 1H, 6-H), 7.02-7.07 (m, 2H, Ar-H), 
7.19-7.22 (m, 1H, Ar-H), 7.27-7.29 (m, 1H, Ar-H), 7.57 (d, J = 5.4 Hz, 1H, HetAr), 
7.73 (d, J = 5.4 Hz, 1H, HetAr), 8.46 (d, J = 5.7 Hz, 1H, 5-H) ppm. 13CNMR (75.4 
MHz, CDCl3): δ 55.9 (OMe), 103.3 (6-CH), 113.0 (CH), 121.2 (CH), 121.9 (C), 122.96 
(CH), 125.1 (CH), 127.1 (CH), 130.5 (CH), 141.9 (C), 148.9 (5-CH), 151.8 (C), 158.6 
(C), 160.4 (C) ppm. HRMS (EI-TOF): Calcd for C14H11NO2S: [M+] 257.0511. Found 
257.0513. 
 
4.1.2.5. 7-(3-methoxyphenoxy)thieno[3,2-b]pyridine (2e): From compound 1 (140 mg, 
0.488 mmol) and 3-methoxyphenol, and after purification by column chromatography 
using a solvent gradient from 30% ether/ petroleum ether to 70% ether/petroleum ether, 
compound 2ewas obtained as a yellow oil (61.0 mg, 55%). 1H NMR (400 MHz, 
CDCl3): δ 3.82 (s, 3H, OMe), 6.62 (d, J = 5.6 Hz, 1H, 6-H), 6.75 (apparent t, J = 2.4 Hz, 
1H, 2’-H), 6.77-6.79 (m, 1H, Ar-H), 6.83-6.86 (m, 1H, Ar-H),7.34 (apparent t, J = 8.4 
Hz, 1H, 5’-H), 7.58 (d, J = 5.2 Hz, 1H, HetAr), 7.74 (d, J = 5.2 Hz, 1H, HetAr), 8.51 (d, 
J = 5.6 Hz, 1H, 5-H) ppm. 13CNMR(100.6 MHz, CDCl3): δ 55.5 (OMe), 104.4 (6-CH), 
106.8 (2’-CH), 111.6 (CH), 112.9 (CH), 122.8 (C), 125.2 (CH), 130.5 (5’-CH), 130.6 
(CH), 149.1 (5-CH), 154.8 (C), 158.9 (C), 160.1 (C), 161.1 (C) ppm. HRMS (EI-TOF): 
Calcd for C14H11NO2S: [M+] 257.0511. Found 257.0509. 
 
4.1.2.6. 7-(4-methoxyphenoxy)thieno[3,2-b]pyridine (2f): From compound 1 (140 mg, 
0.488 mmol) and 4-methoxyphenol, and after purification by column chromatography 
using a solvent gradient from 30% ether/ petroleum ether to 70% ether/petroleum ether, 
compound 2f was obtained as a yellow solid (50.0 mg, 45%), m.p 70.5-72.1 ºC. 1H 
NMR (400 MHz, CDCl3): δ 3.86 (s, 3H, OMe), 6.53 (d, J = 5.2 Hz, 1H, 6-H), 6.98 (d, J 
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= 9.2 Hz, 2H, 3’ and 5’-H), 7.13 (d, J = 9.2 Hz, 2H, 2´ and 6’-H), 7.59 (d, J = 5.6 Hz, 
1H, HetAr), 7.75 (d, J = 5.6 Hz, 1H, HetAr), 8.49 (d, J = 5.2 Hz, 1H, 5-H) ppm. 
13CNMR (100.6 MHz, CDCl3): δ 55.6 (OMe), 103.6 (6-CH), 115.1 (3’ and 5’-CH), 
122.2 (2’ and 6’-CH), 122.5 (C), 125.1 (CH),130.7 (CH), 146.9 (C), 148.9 (5-CH), 
157.4 (C), 158.5 (C), 161.1 (C) ppm. HRMS (EI-TOF): Calcd for C14H11NO2S: [M+] 
257.0511. Found 257.0512. 
 
4.1.3. General procedure for the synthesis of di(hetero)arylamines 3a-f: A dry Schlenk 
tube was charged under Ar with dry toluene (3 mL), the fluoro or methoxyanilines (1.1 
equiv.), Pd(OAc)2 (6 mol%), BINAP(8 mol%), Cs2CO3 (2 equiv.) andcompound1. The 
mixture was heated with stirring under Ar at 100 ºC for 2h. After cooling water (5mL) 
and ethyl acetate (5mL) were added. The phases were separated and the aqueous phase 
was extracted with more ethyl acetate (2×5mL). The organic phase was dried (MgSO4) 
and filtered. Removal of the solvent gave a solid which was submitted to a dry flashin 
silica using ether or AcOEt and a solid was obtained. 
 
 
4.1.3.1. N-(2-fluorophenyl)thieno[3,2-b]pyridin-7-amine (3a): From compound 1 
(200mg, 0.940 mmol) and 2-fluoroaniline, compound 3awas obtained as a yellow 
solid(148mg, 65%),m.p. 134-135 ºC. 1H NMR (400 MHz, DMSO-d6): δ 6.43 (d, J = 5.2 
Hz, 1H, 6-H), 7.24-7.37 (m, 4H, Ar-H), 7.42 (d, J = 5.6 Hz, 1H, HetAr-H), 7.95 (d, J = 
5.6 Hz, 1H, HetAr-H), 8.26 (d, J = 5.2 Hz, 1H, 5-H), 8.76 (br s, 1H, NH) ppm. 13CNMR 
(100.6 MHz, DMSO-d6): δ 102.4 (6-CH), 116.4 (d, J = 20.0 Hz, 3’-CH), 119.1 (C), 
124.9 (d, J = 6.0 Hz, CH), 125.0 (CH), 126.9 (d, J = 8 Hz,CH), 127.2 (d, J = 12.0 Hz, 
1’-C), 127.50 (CH), 130.1 (CH), 146.8 (C), 148.01 (5-CH), 157.4 (C), 156.7 (d, J = 
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246.5 Hz, CF) ppm. HRMS (EI-TOF): Calcd for C13H9FN2S [M+] 244.0470. Found 
244.0473. 
 
4.1.3.2. N-(3-fluorophenyl)thieno[3,2-b]pyridin-7-amine (3b): From compound 1 
(200mg, 0.940 mmol) and 3-fluoroaniline, compound 3b was obtained as a yellow solid 
(180mg, 83%), m.p. 186-187ºC. 1H NMR (400 MHz, DMSO-d6): δ 6.86-6.89 (m, 1H, 
Ar-H), 7.00 (d, J = 5.2 Hz, 1H, 6-H), 7.06-7.13 (m, 2H, Ar-H), 7.37-7.39 (m, 1H, Ar-
H), 7.46 (d, J = 5.6 Hz, 1H, HetAr-H), 8.00 (d, J = 5.6 Hz, 1H, HetAr-H), 8.36 (d, J = 
5.2 Hz, 1H, 5-H), 9.00 (br s, 1H,NH) ppm. 13CNMR (100.6 MHz, DMSO-d6): δ 103.2 
(6-CH), 107.6 (d, J = 24.0 Hz, CH), 109.4 (d, J = 22.0 Hz, CH), 116.7 (d, J = 2.0 Hz, 
6’-CH), 120.8 (C), 125.1 (CH), 130.3 (CH), 130.7 (d, J = 10.0 Hz, 5’-CH), 142.4 (d, J = 
10 Hz, 1’-C), 145.2 (C), 148.3 (5-CH), 157.7 (C), 162.6 (d, J = 244.0Hz, CF) ppm. 
HRMS (EI-TOF): Calcd for C13H9FN2S [M+] 244.0470. Found 244.0470. 
 
4.1.3.3. N-(4-fluorophenyl)thieno[3,2-b]pyridin-7-amine (3c): From compound 1 
(200mg, 0.940 mmol) and 4-fluoroaniline, compound 3cwas obtained a yellow solid 
(180mg, 80%), m.p. 184-185ºC. 1H NMR (400 MHz, DMSO-d6): δ 6.75 (d, J = 5.2 Hz, 
1H, 6-H), 7.20-7.24 (m, 2H, 3’ and 5’-H), 7.29-7.32 (m, 2H, 2’ and 6’-H), 7.42 (d, J = 
5.6 Hz, 1H, HetAr-H), 7.96 (d, J = 5.6 Hz, 1H, HetAr-H), 8.27 (d, J = 5.2 Hz, 1H, 5-H), 
8.78 (br s, 1H, NH) ppm. 13CNMR (100.6 MHz, DMSO-d6): δ 101.6 (6-CH), 115.9 (d, J 
= 22.0 Hz, 3’ and 5’-CH), 119.5 (C), 124.7 (d, J = 8.0 Hz, 2’ and 6’-CH), 125.1 (CH), 
130.0 (CH), 136.3 (d, J = 3 Hz, 1’-C), 146.5 (C), 148.2 (5-CH), 157.5 (C), 158.7 (d, J = 
240.0 Hz, CF) ppm. HRMS (EI-TOF): Calcd for C13H9FN2S [M+] 244.0470. Found 
244.0474. 
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4.1.3.4. N-(2-methoxyphenyl)thieno[3,2-b]pyridin-7-amine(3d): from compound 1 
(100 mg, 0.470 mmol) and 2-methoxyaniline, compound 3d was obtained a yellow solid 
(95.0mg, 80%). m.p. 130-131 ºC. 1H NMR (400MHz, DMSO-d6): δ3.73 (s, 3H, OMe), 
6.37 (d, J = 5.2 Hz, 6-H), 6.97-7.01 (m, 1H, ArH), 7.12-7.14 (m, 1H, ArH), 7.22-7.29 
(m, 2H, 2xArH), 7.38 (d, J = 5.6 Hz, 1H, HetArH), 7.91 (d, J = 5.6 Hz, 1H, HetAr-H), 
8.20 (br s, 1H, 5-H), 8.43 (br s, 1H, NH) ppm. 13CNMR (100.6MHz, DMSO-d6): δ 
55.41 (OMe), 102.21 (6-CH), 112.17(CH), 118.58 (C), 120.56 (CH), 124.57(CH), 
126.98 (CH), 127.02 (CH), 127.53 (C), 130.17 (CH), 147.29 (5-CH), 147.85 (C), 
154.27 (C), 156.69 (C) ppm. HRMS (EI-TOF): Calcd for C14H12N2OS [M+] 256.0670. 
Found 256.0675. 
 
4.1.3.5. N-(3-methoxyphenyl)thieno[3,2-b]pyridin-7-amine(3e): From compound 1 
(100 mg, 0.470 mmol) and 3-methoxyaniline, compound 3e was obtained a yellow solid 
(99.0 mg, 83%),m.p. 146-147 ºC. 1H NMR (400MHz,CDCl3): δ3.82 (s, 3H, OMe), 6.67 
(br s, 1H, NH), 6.74-6.77 (m, 1H, 4’-H), 6.84-6.85 (m, 1H, 2’-H), 6.87-6.89 (m, 1H, 6’-
H), 6.98 (d, J = 5.2 Hz, 1H, 6-H), 7.31 (apparent, J = 8.4 Hz, 1H, 5’-H), 7.55 (d, J = 5.6 
Hz, 1H, HetAr-H), 7.65 (d, J = 5.6 Hz, 1H, HetAr-H), 8.39 (d, J = 5.2 Hz, 1H, 5-H), 
ppm. 13CNMR (100.6MHz, CDCl3): δ 55.37 (OMe), 102.40 (6-CH), 108.48 (2’-CH), 
110.33 (4’-CH), 114.88 (6’-CH), 120.72(C), 125.50 (CH), 128.77 (CH), 130.32 (5’-
CH), 140.20 (C), 146.73 (C), 147.52 (5-CH), 156.48 (C), 160.63 (C) ppm. HRMS (EI-
TOF): Calcd for C14H12N2OS [M+] 256.0670. Found 256.0678. 
 
4.1.3.6. N-(4-methoxyphenyl)thieno[3,2-b]pyridin-7-amine(3f): From compound 1 
(100 mg, 0.470 mmol) and 4-methoxyaniline, compound 3f was obtained a yellow solid 
(102 mg, 85%). m.p. 184-185 ºC. 1H NMR (400MHz, DMSO-d6): δ3.76 (s, 3H, OMe), 
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6.61 (d, J = 5.2 Hz, 1H, 6-H), 6.97 (d, J = 8.8 Hz, 2H, 3’ and 5’-H), 7.21 (d, J = 8.8 Hz, 
2H, 2’ and 6’-H), 7.39 (d, J = 5.6 Hz, 1H, HetAr-H), 8.21 (br s, 1H, 5-H), 8.60 (br s, 
1H, NH), ppm. 13CNMR (100.6MHz, DMSO-d6): δ 55.26 (OMe), 101.06 (6-CH), 
114.43 (3’ and 5’-CH), 118.91 (C), 125.07 (CH), 125.55 (2’ and 6’-CH), 129.81 (CH), 
132.44 (C), 147.46 (C), 148.05 (5-CH), 156.38 (C), 157.44 (C) ppm. HRMS (EI-TOF): 
Calcd for C14H12N2OS [M+] 256.0670. Found 256.0677. 
 
4.2. Growth inhibitory activity on human tumor cell lines and on porcine liver 
primary cells 
 
Five human tumor cell lines were used: MCF-7 (breast adenocarcinoma) from DSMZ 
(Leibniz-Institut DSMZ - Deutsche Sammlung von Mikroorganismen und Zellkulturen 
GmbH), NCI-H460 (non-small cell lung carcinoma), HCT15 (colon carcinoma), HeLa 
(cervical carcinoma) and HepG2 (hepatocellular carcinoma) from ECACC (European 
Collection of Cell Cultures). Cells were routinely maintained as adherent cell cultures at 
37 ºC, in a humidified air incubator containing 5% CO2. Cells were cultured in: 
i)RPMI-1640 medium supplemented with10% heat-inactivated fetal bovine serum 
(FBS) and 2 mM glutamine, for the MCF-7, NCI-H460 and HCT15 cell lines and 
ii)DMEM supplemented with 10% FBS, 2 mM glutamine, 100 U/mL penicillin and 100 
mg/mL streptomycin, for HeLa and HepG2 cells). To assess the growth inhibitory 
activity of the compounds, the Sulforhodamine B assay was performed according to a 
procedure previously described by the authors [2-7]. For this, each cell line was plated 
at an appropriate density (7.5 × 103 cells/well for MCF-7, NCI-H460 and HCT15 cells 
or 1.0 × 104 cells/well for HeLa and HepG2 cells) in 96-well plates.  
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For the evaluation of toxicity towards non-tumor cells, a primary cell culture was 
prepared from a freshly harvested porcine liver obtained from a local slaughter house, 
according to a procedure previously established by some of us [6,7]; these cells were 
designated as PLP2 cells. Cell culture was continued with direct monitoring every two 
to three days using a phase contrast microscope. Before confluence was reached, cells 
were sub-cultured and plated in 96-well plates at a density of 1.0×104 cells/well, and 
culturedin DMEM medium with 10% FBS, 100 U/mL penicillin and 100 µg/mL 
streptomycin.  Cells were treated for 48 h with the different compounds solutions and 
the procedure for SRB assay was followed, as described above. The results were 
expressed in GI50 values (concentrations that inhibited 50% of the net cell growth). 
Ellipticine was used as positive control. 
 
4.3. Analysis of cell cycle profile and programmed cell death 
NCI-H460 cells (1×105 cells/well) were plated in 6-well plates and incubated at 37º C 
for 24 h. Cells were then treated with complete medium (blank), with the compounds 
(2e, 3d and 3e)) at their previously determined GI50 concentrations or with their 
respective vehicle (DMSO, control). Cells were harvested following a 24 h and/or 48 h 
and further processed according to the following protocols.For cell cycle profile 
analysis, following 24 h treatment cells were fixed in 70% ice-cold ethanol and kept at 
4ºC for at least 12 h until analysis. Prior to analysis, cells were incubated with 
Propidium Iodide (5 µg/mL) and RNaseA in PBS (100 µg/ml) for 30 min on ice [11]. 
Cellular DNA content was analyzedusing a FACSCalibur (BD) flow cytometer. Cell 
cycle profile was subsequently analyzedusing the FlowJo 7.6.5 software (Tree Star, 
Inc., Ashland, OR, USA) after cell debris and aggregates exclusion [3,4]. 
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For programmed cell death analysis, following 24h and 48 h treatment cells were fixed 
in 4% paraformaldehyde for 30 minutes and further kept in PBS at 4 ºC until analysis. 
Cytospins were then prepared and cells permeabilized in ice cold 0.1% Triton X-100in 
0.1% sodium citrate for 2 min. Programmed cell death was assessed using the “in situ 
cell death detection kit-fluorescein” (Roche, Basel Switzerland).Briefly, cells were 
incubated with the TUNEL reaction mix (enzyme diluted 1:20) for 1 h, as previously 
described [12]. Slides were mounted with Vectashield Mounting Media with DAPI 
(Vector Laboratories). Cells were observed in a DM2000 microscope (LEICA) and a 
semi-quantitative evaluation of the levels of programmed cell death was performed by 
counting a minimum of 500 cells per slide, except in the cases of 2e and 3d treatment at 
48h, in which only ~300 cells were counted. 
 
4.4. Statistical analysis 
Results were expressed as mean ± standard deviation (SD) or standard error (SEM) of at 
least three independent experiments, performed in duplicate. Statistical significance was 
tested with a two tailed paired Student’s t-Test in relation to control (DMSO treatment). 
* p<0.05. 
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